Showing results (81-90 of 132) with videos related to

Sort By:
Pageof 14
Plos One|December 23, 2021
Correction: Phase II Study Evaluating 2 Dosing Schedules of Oral Foretinib (GSK1363089), cMET/VEGFR2 Inhibitor, in Patients with Metastatic Gastric CancerManish A Shah, Zev A Wainberg, Daniel V T Catenacci, et al.
Plos One|October 10, 2022
Correction: Phase II Study Evaluating 2 Dosing Schedules of Oral Foretinib (GSK1363089), cMET/VEGFR2 Inhibitor, in Patients with Metastatic Gastric CancerManish A Shah, Zev A Wainberg, Daniel V T Catenacci, et al.
Future Oncology (London, England)|March 28, 2025
S2303: phase II/III trial of paclitaxel + ramucirumab ± nivolumab in gastric and esophageal adenocarcinoma (PARAMUNE)Anwaar Saeed, Sarah Colby, Paul Eliezer Oberstein, et al.
Cancer|November 16, 2020
Long-term outcomes of pexidartinib in tenosynovial giant cell tumorsHans Gelderblom, Andrew J Wagner, William D Tap, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 21, 2024
DKN-01 in Combination With Tislelizumab and Chemotherapy as First-Line Therapy in Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: DisTinGuishSamuel J Klempner, Mohamad Bassam Sonbol, Zev A Wainberg, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|February 3, 2024
Bemarituzumab as first-line treatment for locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma: final analysis of the randomized phase 2 FIGHT trialZev A Wainberg, Yoon-Koo Kang, Keun-Wook Lee, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 10, 2015
Randomized, Double-Blind, Phase II Study of Ruxolitinib or Placebo in Combination With Capecitabine in Patients With Metastatic Pancreatic Cancer for Whom Therapy With Gemcitabine Has FailedHerbert I Hurwitz, Nikhil Uppal, Stephanie A Wagner, et al.
Future Oncology (London, England)|January 18, 2022
CSF1 receptor inhibition of tenosynovial giant cell tumor using novel disease-specific MRI measures of tumor burdenCharles Peterfy, Yan Chen, Peter Countryman, et al.
European Journal of Cancer (Oxford, England : 1990)|January 10, 2025
A first-in-human phase 1/2 dose-escalation study of MAK683 (EED inhibitor) in patients with advanced malignanciesVincent Ribrag, Lara Iglesias, Filippo De Braud, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 3, 2022
Association of Tumor Mutational Burden with Efficacy of Pembrolizumab±Chemotherapy as First-Line Therapy for Gastric Cancer in the Phase III KEYNOTE-062 StudyKeun-Wook Lee, Eric Van Cutsem, Yung-Jue Bang, et al.
Pageof 14